Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

Selank

Cat 2 → Pending Cat 1

Neuropeptide · Research peptide (approved in Russia)

Synthetic analog of tuftsin researched for anxiolytic and immunomodulatory effects. Approved in Russia; not FDA-approved in the US.

About

Mechanism

Synthetic analog of the immunomodulatory peptide tuftsin with a stabilizing Pro-Gly-Pro sequence. Modulates GABA-A receptor expression, enhances enkephalin levels, and provides anxiolytic effects without sedation or dependence.

Half-Life

Approximately 3-5 minutes (intranasal delivery extends effective duration)

Route

subcutaneous

Frequency

Once daily (intranasal or SC)

Clinical Dosing

200-400 mcgonce daily (intranasal or sc)

Not FDA-approved. Approved in Russia for anxiety and cognitive function. Currently FDA Category 2 (restricted) in US. Pending return to Category 1.

Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence.

Regulatory Status

FDA Category

Research peptide in US (approved in Russia)

Reclassification

pending

Date Restricted

2023-09-29

Announced Return

2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Protocol

Source: Zozulya et al., Bulletin of Experimental Biology and Medicine, 2008

Dose	Duration	Draw (3 mg vial in 2mL)	Notes
300 mcg	Maintenance	0.20 mL (20 units)	Standard research dose

Available Vial Sizes

3 mg

3 mg vial

5 mg

5 mg vial

Citations

[1]Selank: A Novel Anxiolytic Peptide. Bulletin of Experimental Biology and Medicine, 145(2), 225-227. Link(Reviewed: 2026-02-27)